Long-term effects of statin treatment in elderly people: extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)

Simple item page
dc.contributor.authorLloyd, Suzanne M.
dc.contributor.authorStott, David J.
dc.contributor.authorde Craen, Anton J. M.
dc.contributor.authorKearney, Patricia M.
dc.contributor.authorSattar, Naveed
dc.contributor.authorPerry, Ivan J.
dc.contributor.authorPackard, Christopher J.
dc.contributor.authorBriggs, Andrew
dc.contributor.authorMarchbank, Laura
dc.contributor.authorComber, Harry
dc.contributor.authorJukema, J. Wouter
dc.contributor.authorWestendorp, Rudi G. J.
dc.contributor.authorTrompet, Stella
dc.contributor.authorBuckley, Brendan M.
dc.contributor.authorFord, Ian
dc.contributor.funderWellcome Trust, United Kingdomen
dc.contributor.funderChief Scientist Office, Scotlanden
dc.date.accessioned2014-04-04T15:01:00Z
dc.date.available2014-04-04T15:01:00Z
dc.date.issued2013-09-02
dc.date.updated2013-11-28T14:36:10Z
dc.description.abstractBackground The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), a placebo-controlled trial of pravastatin, demonstrated a 19% reduction in coronary outcomes (p = 0.006) after a mean of 3.2 years, with no impact on stroke outcomes or all-cause mortality. However, there was a suggestion of increased cancer risk. Our aim is to determine the long-term benefits and safety of pravastatin treatment in older people using post-trial follow-up of the PROSPER participants. Methods: 5,804 (2,520 Scottish) men and women aged 70–82 years with either pre-existing vascular disease or increased risk of such disease because of smoking, hypertension or diabetes, were randomised to 40 mg pravastatin or matching placebo. Using record linkage to routinely collected health records, all participants (full cohort) were linked to death and cancer registries, and the Scottish cohort additionally to hospital admissions, to provide composite fatal/non-fatal cardiovascular outcomes (total mean follow-up 8.6 years). Results: Pravastatin treatment for 3.2 years reduced CHD death in the full cohort, hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.68–0.95, p = 0.0091 and fatal coronary events or coronary hospitalisations in the Scottish cohort (HR 0.81, 95% CI 0.69–0.95, p = 0.0081) over 8.6 years. There was no reduction in stroke or all-cause mortality. Cancer risk was not increased in the full cohort (HR 1.08, 95% CI 0.96–1.21, p = 0.22). Conclusions: Pravastatin treatment of elderly high-risk subjects for 3.2 years provided long-term protection against CHD events and CHD mortality. However, this was not associated with any increase in life expectancy, possibly due to competing mortality with deaths from other causes. There was no evidence of long-term increased risk of cancer.en
dc.description.sponsorshipWellcome Trust, United Kingdom (Scottish Health Informatics Programme)
dc.description.statusPeer revieweden
dc.description.versionPublished Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationLLOYD, S. M., STOTT, D. J., DE CRAEN, A. J. M., KEARNEY, P. M., SATTAR, N., PERRY, I., PACKARD, C. J., BRIGGS, A., MARCHBANK, L., COMBER, H., JUKEMA, J. W., WESTENDORP, R. G. J., TROMPET, S., BUCKLEY, B. M. & FORD, I. 2013. Long-term effects of statin treatment in elderly people: extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). PLoS ONE 8(9): e72642. doi:10.1371/journal.pone.0072642en
dc.identifier.doi10.1371/journal.pone.0072642
dc.identifier.issn1932-6203
dc.identifier.issued9en
dc.identifier.journaltitlePlos Oneen
dc.identifier.startpagee72642en
dc.identifier.urihttps://hdl.handle.net/10468/1508
dc.identifier.volume8en
dc.language.isoenen
dc.publisherPublic Library of Scienceen
dc.rights©2013 Lloyd et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.en
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/en
dc.subjectCancer treatmenten
dc.subjectCoronary artery diseaseen
dc.subjectCoronary heart diseaseen
dc.subjectDeath ratesen
dc.subjectElderlyen
dc.subjectStrokeen
dc.subjectVascular diseasesen
dc.titleLong-term effects of statin treatment in elderly people: extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)en
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
Plos_one_0072642.pdf
Size:
655.03 KB
Format:
Adobe Portable Document Format
Description:
Published Version
Download
Thumbnail Image
Name:
journal.pone.0072642.s001.docx
Size:
19.45 KB
Format:
Microsoft Word XML
Description:
Supplementary Files
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Public Health - Journal Articles
Pharmacology and Therapeutics - Journal Articles